#United States #San Francisco #Modern Healthcare #Cytovale #IntelliSep

Cytovale's IntelliSep Honored by Modern Healthcare

Cytovale®, a pioneering name in medical diagnostics, has garnered significant attention recently with the recognition of its groundbreaking sepsis detection solution, IntelliSep. The company was honored by Modern Healthcare as one of the Best in Business for 2024 in the laboratory medicine and medical technology sectors. This accolade highlights the impact of Cytovale's technology in enhancing patient care and hospital efficiency.

Acknowledgment from Modern Healthcare

The Best in Business awards by Modern Healthcare serve to celebrate organizations that demonstrate outstanding innovation and effectiveness in the healthcare landscape. Dan Peres, president of Modern Healthcare, stated that the recipients show unwavering commitment to driving meaningful change within the industry. Cytovale's recognition not only reflects its dedication to improving healthcare outcomes but also highlights its role in setting new standards for medical practices.

IntelliSep: A Game-Changer in Sepsis Detection

Cytovale's IntelliSep is the first and only FDA-cleared cellular host diagnostic approved for emergency department use, a critical area where the majority of sepsis cases are identified. The IntelliSep test requires just a standard blood draw and delivers crucial insights into the biological factors associated with sepsis in under eight minutes. Subsequently, this swift analysis enables healthcare teams to diagnose conditions with enhanced confidence and deliver effective treatment promptly.

Implemented first within the Franciscan Missionaries of Our Lady Health System spanning Louisiana and Mississippi, IntelliSep has exhibited remarkable outcomes. Reports indicate that hospitals utilizing this technology have experienced a 30% reduction in the risk-adjusted mortality index among sepsis patients. Moreover, patients identified as at risk for sepsis receive treatment 60 to 70 minutes earlier than average, demonstrating IntelliSep’s significant contribution to expediting healthcare responses.

Real-World Impact on Patient Care and Cost Savings

Cytovale's technology not only aids in clinical diagnoses but also translates to tangible savings for the healthcare system. Patients whose treatment involved IntelliSep spent, on average, 1.28 fewer days in the hospital, contributing to an estimated saving of $1,429 for each patient subjected to the test. The implications of these efficiencies are substantial, especially given the high costs associated with prolonged hospital stays and complex treatment paths for sepsis.

Ajay Shah, co-founder and CEO of Cytovale, emphasized the critical nature of addressing sepsis, noting that it surpasses heart attacks and strokes in both mortality and healthcare costs. He expressed pride in IntelliSep's proven clinical impact and the recognition received, reaffirming Cytovale’s commitment to collaboration with hospitals nationwide to enhance patient care services.

Further Recognition and Future Directions

Earlier in the year, Cytovale was awarded the Digital Health Hub Foundation’s title for the Biggest Healthcare Savings Story, reiterating the company’s dedication to creating financial efficiencies alongside medical advancements. Additionally, IntelliSep’s journey saw it being listed in Inc. magazine’s 2024 Best in Business rankings, solidifying its reputation as a leader in sepsis diagnostics.

Cytovale remains at the forefront of innovation in early detection technologies, having developed a solution that not only identifies immune response discrepancies indicative of sepsis but does so within an unprecedented timeframe. As the company continues its mission, it remains focused on enhancing the lives of patients and optimizing healthcare delivery through strategic partnerships and technological expansion.

In closing, Cytovale’s recognition by Modern Healthcare is not just a badge of honor; it symbolizes a forward momentum in the battle against sepsis, ultimately aiming for better health outcomes across the healthcare industry.

For more insights on Cytovale and IntelliSep, please visit Cytovale's website or follow them on LinkedIn and X.